Truist Raises Price Targets on Eli Lilly and Exelixis
Truist Securities lifted its Eli Lilly price target to $1612 from $1376 and its Exelixis target to $60 from $54, keeping Exelixis at Hold.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Truist Securities raised its price target on Eli Lilly to $1612 per share on October 30, 2026, up from $1376.
For Exelixis, the firm lifted its target to $60 from $54 and kept its Hold rating unchanged.
The changes were reported by Dow Jones Newswires, which cited Benzinga as the source.
why it matters
Analyst target changes reflect one firm's view of future value and rarely move a stock on their own. Investors usually weigh them alongside earnings, drug pipeline news and broader sector trends, especially for large drugmakers such as Eli Lilly.
tags
instruments
sources
- Eli Lilly Price Target Raised to $1612.00/Share From $1376.00 by Truist Securities — Dow Jones Newswires, 30 October 2026 at 15:58 UTC
- Exelixis Price Target Raised to $60.00/Share From $54.00 by Truist Securities — Dow Jones Newswires, 30 October 2026 at 16:16 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗